Could GLP-1 Medications Change the Future of Ovarian Cancer Care?

GLP-1 medications have become well known for helping people manage type 2 diabetes and lose weight. Now, researchers are studying whether these same drugs might do something far more surprising: help slow the spread of certain cancers, including ovarian cancer.

Early findings suggest that GLP-1 activity may support the body's natural defenses against tumor growth, and that could open new doors for patients and their care teams.

Here's what the science shows so far, and what two gynecologic oncologists at Baptist Health want you to understand about this developing field.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1, a hormone your body makes naturally. It helps regulate blood sugar, control appetite and manage how your body processes food. GLP-1 medications mimic this hormone, which is why they've become popular tools for treating diabetes and obesity.

But the story doesn't end with blood sugar and weight. Scientists have noticed that GLP-1 seems to influence the body in broader ways, including how cells respond to inflammation and stress. Those two factors play a major role in how cancer develops and spreads.

"When we first began prescribing these medications, the focus was almost entirely on metabolic health," said John P. Diaz, M.D., gynecologic oncologist at Baptist Health Herbert Wertheim Cancer Institute, chief of gynecologic oncology at Baptist Health, and director of robotic surgery and lead physician for clinical trials in gynecologic oncology at the Institute. "What we're seeing now is that GLP-1 may have effects that reach well beyond blood sugar, and that has real implications for how we think about cancer care."

The Connection Between Inflammation and cancer

Chronic inflammation is one of the body's silent troublemakers. When inflammation lingers, it can damage healthy cells and create an environment where cancer cells thrive. Ovarian cancer, in particular, has been linked to inflammatory processes that help tumors grow and spread.

This is where GLP-1 medications may offer an advantage. Research suggests these drugs can reduce inflammation throughout the body. By calming that inflammatory environment, GLP-1 activity may make it harder for cancer cells to gain a foothold.

"Inflammation acts almost like fuel for certain cancers," Dr. Diaz said. "If a medication can reduce that inflammation, we may be giving the body a better chance to slow tumor growth. That's an exciting possibility, and it's one we're watching closely in ovarian cancer specifically."

Thomas P. Morrissey, M.D., director of gynecologic oncology at Lynn Cancer Institute, part of Baptist Health at Boca Raton Regional Hospital, said that the inflammation link deserves serious attention.

"We've long suspected that a highly inflammatory state may worsen outcomes for many of our patients," Dr. Morrissey said. "The idea that a widely available medication might help lower that inflammation is intriguing. It will not replace our standard treatments, but it could become a valuable piece of the puzzle."

How Cells Respond to Stress

Cancer cells are remarkably good at surviving under stress. They adapt to low oxygen, resist treatment and find ways to keep growing when they shouldn't. Part of what makes GLP-1 medications interesting is their potential effect on how cells handle this kind of stress.

Studies suggest GLP-1 activity may improve the way healthy cells respond to stress signals, which in turn may help the body better recognize and fight abnormal cells. When the body's stress response works properly, it can support the immune system's ability to target tumors.

"Think of it this way: healthy cells that respond well to stress are better equipped to protect the body," Dr. Morrissey said. "If GLP-1 medications can strengthen that response, they may help the body do a better job of keeping cancer in check. We're still confirming exactly how this works, but the early signals are encouraging."

What the Research Shows So Far

Much of the current human evidence comes from observational studies, which have reported that people taking GLP-1 receptor agonists appear to have a lower incidence of ovarian cancer than comparable individuals not taking these medications. While these findings suggest a potentially protective association, they do not establish that GLP-1 medications directly prevent cancer.

Researchers continue to investigate why this association exists. Possible explanations include the medications' anti-inflammatory effects, improvements in insulin resistance and other aspects of metabolic health, or the weight loss many patients experience while taking them. At this point, scientists do not know which of these factors—or what combination of them—may be responsible.

Evidence suggesting that GLP-1 medications improve survival after an ovarian cancer diagnosis is much more limited. Although a few early studies have raised questions about whether GLP-1 activity could influence cancer outcomes, larger clinical studies are needed before researchers can determine whether these medications affect survival or should play a role in cancer treatment.

"When we see data suggesting that higher GLP-1 activity is associated with longer survival, we take notice," Dr. Diaz said. "It tells us there may be a biological benefit we haven't fully tapped into yet. Our job now is to study it carefully so we can understand who might benefit and how."

An Important Word of Caution

Both physicians stress that this research is still in its early stages. GLP-1 medications are not approved as a cancer treatment, and no one should start or stop any medication based on emerging studies alone.

"We need to be very clear with patients," Dr. Morrissey said. "These findings are promising, but they are not a reason to view GLP-1 drugs as a cancer cure. What they represent is a new avenue of research that could eventually improve how we care for people. That's different from a proven therapy."

Dr. Diaz encourages patients to keep the conversation grounded in facts.

"Hope is important, and so is honesty," Dr. Diaz said. "We're optimistic about what this research could mean, but we owe it to our patients to wait for strong evidence before changing how we treat ovarian cancer. In the meantime, proven treatments like surgery, chemotherapy and targeted therapies remain the foundation of care."

What This Means for You

If you or a loved one is managing ovarian cancer, or living with diabetes or obesity, you may be wondering how this research applies to your situation. The best step is to talk openly with your care team about your health history, your medications and any questions you have.

Your physician can help you understand:

• Whether GLP-1 medications are appropriate for your overall health

• How your treatment plan fits your specific diagnosis

• What clinical trials or new research might be relevant to you

"Every patient is different, and that's exactly why these conversations matter," Dr. Morrissey said. "We look at the whole person, not just one lab value or one medication. That personalized approach is how we deliver the best possible care."

Looking Ahead

The link between GLP-1 medications and ovarian cancer is one of the more intriguing areas of current research. Early studies suggest these medications may influence biological processes such as inflammation and cellular stress, and observational research has identified a potential association with a lower risk of developing ovarian cancer.

Whether these findings reflect the effects of the medications themselves, weight loss, or improvements in overall metabolic health remains an active area of investigation. More rigorous clinical studies will be needed to determine whether GLP-1 medications have a future role in cancer prevention or treatment.

For now, the message from Baptist Health's specialists is one of cautious optimism. The science is moving forward, and patients can take comfort in knowing that dedicated research teams are working to turn these early discoveries into real benefits.

"This is what progress looks like," Dr. Diaz said. "We ask questions; we study the evidence; and we stay committed to improving outcomes. That's how breakthroughs happen, and that's what our patients deserve."